J. Gainor

发表

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

L. Crinò, J. Aerts, E. Vokes, 2015, The New England journal of medicine.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

J. Szustakowski, P. Stephens, C. Rudin, 2018, Cancer discovery.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2011, The Lancet. Oncology.

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Manish R. Patel, H. Burris, J. Frederick, 2019, Journal of Clinical Oncology.

Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).

A. Saqi, N. Rizvi, M. Bacchetta, 2018 .

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Shibing Deng, Hui Wang, Shinji Yamazaki, 2015, Cancer cell.

Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.

T. Burns, A. Shaw, C. Lovly, 2020, Clinical lung cancer.

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

S. Digumarthy, L. Sequist, A. Shaw, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Ahmet Zehir, Ronglai Shen, Barry S Taylor, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

S. Digumarthy, J. Roth, M. Mino‐Kenudson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.

S. Digumarthy, J. Heymach, M. Hellmann, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

S. Digumarthy, A. Iafrate, C. Channick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model.

B. Furie, C. Dubois, L. Panicot-Dubois, 2007, The Journal of clinical investigation.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

A. Mansfield, Michael Thomas, R. Doebele, 2021, The Lancet. Oncology.

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer

S. Rodig, S. Alden, M. Nishino, 2021, Journal for ImmunoTherapy of Cancer.

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

M. Lanuti, A. Saqi, N. Rizvi, 2020, The Lancet. Oncology.

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States

C. Kong, K. Reynolds, Steven D Criss, 2019, JAMA network open.

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System

C. Kong, K. Reynolds, Deirdre F Sheehan, 2019, JAMA oncology.

Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment

G. Getz, C. Stewart, Jaegil Kim, 2018, bioRxiv.

Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance

M. Mino‐Kenudson, Y. Hung, J. Gainor, 2021, Modern Pathology.

Cost‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer

Jeffrey W. Clark, D. Chung, C. Hur, 2018, Cancer.

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

A. Madabhushi, M. Mino‐Kenudson, R. Herbst, 2022, Journal for ImmunoTherapy of Cancer.

Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade.

R. Barzilay, S. Digumarthy, M. Kris, 2020, Cancer discovery.

Molecular Analysis of Plasma From Patients With ROS1‐Positive NSCLC

A. Shaw, J. Lennerz, J. Gainor, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.

P. Brastianos, H. Shih, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss.

T. Neilan, J. Gainor, Melissa C. Price, 2018, The New England journal of medicine.

Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors

J. Temel, J. Greer, A. El-Jawahri, 2020, Cancer.

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

J. Schellens, Sunil Sharma, A. Naing, 2020, Journal for ImmunoTherapy of Cancer.

Putting the brakes on CTLA-4 inhibition in lung cancer?

J. Gainor, M. Mooradian, 2018, Translational lung cancer research.

Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.

J. Gainor, 2018, Journal of thoracic disease.

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

J. Gainor, Benjamin Herzberg, M. Campo, 2017, The oncologist.

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

C. Azzoli, L. Sequist, A. Shaw, 2021, ESMO open.

Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.

J. Gainor, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Xihong Lin, P. Jänne, M. Tolstorukov, 2022, JAMA oncology.

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.

M. Ladanyi, A. Drilon, J. Reis-Filho, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant PD-L1 blockade in non-small-cell lung cancer

J. Gainor, 2021, The Lancet.

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

T. R. Johnson, M. Mino‐Kenudson, B. Yeap, 2022, Nature Cancer.

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis

A. Giobbie-Hurder, R. Sullivan, A. Shaw, 2017, Journal of immunotherapy.

Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.

H. Shih, R. Heist, H. Willers, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

David R. Jones, M. Kris, Benjamin Izar, 2018, Lung cancer.

Spirometry at diagnosis and overall survival in non‐small cell lung cancer patients

Robert Brown, M. Lanuti, Yi Li, 2022, Cancer medicine.

Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain.

J. Gainor, Alissa J. Cooper, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Alectinib in Patients with ALK‐Positive NSCLC and Symptomatic or Large CNS Metastases

S. Digumarthy, A. Shaw, B. Yeap, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

M. Ladanyi, A. Iafrate, M. Mino‐Kenudson, 2013, Clinical Cancer Research.

Low multiplicity of infection of Helicobacter pylori suppresses apoptosis of B lymphocytes.

F. Bussière, M. Asim, W. Khan, 2006, Cancer research.

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

O. Elemento, J. Wolchok, M. Hellmann, 2022, The Journal of experimental medicine.

A coming of age for immune checkpoint inhibitors in cancer.

R. Nipp, J. Gainor, 2019, Immunotherapy.

Impact of Age on Outcomes with Immunotherapy in Patients with Non–Small Cell Lung Cancer

A. Muzikansky, R. Nipp, J. Gainor, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J. Riess, M. Hellmann, H. Rizvi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of Combined PD‐1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer

H. Shih, A. Shaw, N. Horick, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

J. Riess, J. Heymach, M. Hellmann, 2019, Journal of Clinical Oncology.

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

W. Hahn, A. Redig, N. Ilić, 2017, eLife.

Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Michael Thomas, R. Doebele, G. Curigliano, 2019, Journal of Clinical Oncology.

Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

G. Curigliano, Dong-Wan Kim, M. Schuler, 2019, Journal of Clinical Oncology.

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

A. Shaw, Melissa L. Johnson, E. Felip, 2020, Targeted Oncology.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer

Y. Shentu, B. Cho, N. Reguart, 2022, Clinical lung cancer.

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center

Corey L McEwen, R. Sullivan, G. Boland, 2021, The oncologist.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

A. Mansfield, G. Curigliano, M. Schuler, 2021, The lancet. Diabetes & endocrinology.

Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.

Y. Houvras, A. Mansfield, J. Mazières, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

A. Shaw, R. Heist, A. Muzikansky, 2022, JTO clinical and research reports.

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

A. Iafrate, R. Sullivan, A. Bardia, 2022, Cancer Cell.

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

M. Mino‐Kenudson, L. Sequist, R. Heist, 2022, JTO clinical and research reports.

Ponatinib: Accelerated Disapproval.

B. Chabner, J. Gainor, 2015, The oncologist.

Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.

B. Yeap, H. Willers, S. Kamran, 2021, JAMA oncology.

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

J. Desai, K. Flaherty, B. Goh, 2016 .

Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

N. Girard, K. O'Byrne, S. Ramalingam, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016 .

An early look at selective RET inhibitor resistance: new challenges and opportunities

J. Gainor, Jessica J. Lin, 2021, British Journal of Cancer.

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

R. Sullivan, D. Lawrence, K. Reynolds, 2019, Seminars in arthritis and rheumatism.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016, Cancer discovery.

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse

S. Digumarthy, A. Shaw, R. Heist, 2022, JCO precision oncology.

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

J. Pons, P. Squifflet, W. Kim, 2019, Blood.

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

F. Hodi, Y. Bang, P. LoRusso, 2019, Journal of Clinical Oncology.

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

J. Gainor, Z. Piotrowska, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors Associated with Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.

B. Yeap, A. Abbattista, J. Gainor, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

A. Iafrate, A. Bardia, H. Willers, 2021, Cancer Cell.

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

A. Shaw, J. Gainor, Alice T Shaw, 2013, The oncologist.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers

A. Drilon, M. Kris, D. Carbone, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ef ﬁ cacy of Platinum/Pemetrexed Combination Chemotherapy in ALK -Positive NSCLC Refractory to Second-Generation ALK Inhibitors

S. Digumarthy, A. Shaw, Gregory Riely, 2020 .

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

A combinatorial strategy for treating KRAS mutant lung cancer

C. Rudin, S. Lowe, J. Engelman, 2016, Nature.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

G. Getz, A. Iafrate, J. Engelman, 2016, The New England journal of medicine.

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

M. Mino‐Kenudson, J. Engelman, Shigeo Sato, 2015, EBioMedicine.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

J. Engelman, A. Shaw, B. Yeap, 2015, Clinical Cancer Research.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Sridhar Ramaswamy, Mari Mino-Kenudson, Ryohei Katayama, 2014, Science.

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

A. Iafrate, J. Engelman, Y. Okuno, 2014, Clinical Cancer Research.

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Makoto Nishio, Peter McNamara, Ryohei Katayama, 2014, Cancer discovery.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.

A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).

J. Frederick, D. Cho, T. Zaks, 2019, Journal of Global Oncology.

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer

L. Sequist, R. Heist, B. Solomon, 2021, The Lancet.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

A. Shaw, J. Gainor, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation.

R. Heist, D. Juric, J. Lennerz, 2021, Cancer discovery.

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

John G Doench, W. Hahn, A. Redig, 2017, eLife.

Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer

Jeffrey W. Clark, B. Chabner, J. Gainor, 2013, Pharmacological Reviews.

Selective Targeting of RET Fusions in Lung Cancer.

J. Gainor, Jessica J. Lin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

S. Digumarthy, Y. Yagi, C. Azzoli, 2016, Clinical Cancer Research.

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer

C. Perou, C. Rudin, G. Freeman, 2021, Nature Cancer.

Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer

J. Gainor, A. Gavralidis, 2020, Cancer journal.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Cancer Research.

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

A. Niemierko, H. Hubbeling, J. Gainor, 2017, JAMA oncology.

Programmed Cell Death Ligand 1 ( PD-L 1 ) Expression in Resected Lung Adenocarcinomas : Association with Immune Microenvironment

M. Mino‐Kenudson, E. Mark, J. Engelman, 2016 .

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Targeting ALK Rearrangements

A. Shaw, J. Gainor, 2014 .

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

Steven H. Lin, D. Gibbons, M. Routbort, 2023, Nature Communications.

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

A. Giobbie-Hurder, S. Digumarthy, H. Wakimoto, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation

S. Digumarthy, R. Heist, J. Lennerz, 2021, Cancers.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Jeffrey W. Clark, L. Sequist, J. Engelman, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Zhongming Zhao, A. Iafrate, P. Jia, 2016, The oncologist.

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

A. Drilon, B. Tuch, S. Dawson, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.

A. Shaw, J. Gainor, I. Dagogo-Jack, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

M. Lawrence, G. Caponigro, J. Engelman, 2018, Nature Medicine.

Programmed death‐ligand 1 testing in patients with non–small cell lung cancer: Ready for prime time?

J. Gainor, 2017, Cancer cytopathology.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

A. Shaw, B. Yeap, J. Lennerz, 2019, Clinical Cancer Research.

Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies

L. Sequist, J. Engelman, P. Fidias, 2016, Journal of Thoracic Oncology.

Liquid Biopsy, Diagnostic Imaging, and Future Synergies.

S. Digumarthy, P. Pandharipande, S. Raoof, 2022, Journal of the American College of Radiology : JACR.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

P. Brastianos, A. Shaw, A. Chi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Mari Mino-Kenudson, Ryohei Katayama, Sidra Mahmood, 2013, The New England journal of medicine.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Markus Riester, Cyril H Benes, S. Digumarthy, 2018, JCO precision oncology.

Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.

S. Digumarthy, A. Shaw, B. Yeap, 2018 .

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

M. Lawrence, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Programmed Cell Death Ligand (PD‐L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

M. Mino‐Kenudson, E. Mark, J. Engelman, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genotyping lung cancer is an investment in the future.

E. Lamont, C. Azzoli, L. Sequist, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2022, Journal for ImmunoTherapy of Cancer.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.

A. Shaw, S. Ou, J. Gainor, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

K. Reynolds, F. Fintelmann, T. Neilan, 2019, The oncologist.

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.

R. Sullivan, K. Flaherty, Susanna I. Lee, 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

M. Lawrence, S. Digumarthy, C. Azzoli, 2020, Clinical Cancer Research.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diminished Ef ﬁ cacy of Programmed Death-(Ligand)1 Inhibition in STK11 - and KEAP1 -Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

S. Digumarthy, M. Tolstorukov, A. Cherniack, 2022 .

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

J. Bauman, H. Burris, J. Frederick, 2020 .

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer

M. Mino‐Kenudson, L. Sequist, A. Shaw, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state

Linda T. Nieman, Ben S. Wittner, B. Wittner, 2023, Cell reports.

Survival in a case of diffuse alveolar hemorrhage due to Strongyloides stercoralis hyperinfection

J. Gainor, D. J. Beer, D. Steinhaus, 2012, Respiratory medicine case reports.

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

M. Lawrence, S. Digumarthy, A. Drilon, 2021, Clinical Cancer Research.

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition

M. Lawrence, M. Mino‐Kenudson, A. Shaw, 2020, npj Precision Oncology.

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements

S. Digumarthy, A. Shaw, B. Yeap, 2020, Cancers.

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.

S. Digumarthy, L. Sequist, A. Shaw, 2019, Clinical lung cancer.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017 .

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

Fast, Food and Ceritinib in ALK-Positive NSCLC.

A. Shaw, J. Gainor, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, A. Shaw, 2017, JCO precision oncology.

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer

Lauren L. Ritterhouse, A. Iafrate, M. Mino‐Kenudson, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The new kid on the block: RET in lung cancer.

A. Shaw, J. Gainor, 2013, Cancer discovery.

Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status.

S. Digumarthy, M. Tolstorukov, A. Cherniack, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule.

N. Gray, T. Mok, J. Gainor, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Predictive Biomarkers and Personalized Medicine ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1 , 683 Patients with Non – Small Cell Lung Cancer

M. Ladanyi, A. Iafrate, M. Mino‐Kenudson, 2013 .

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.

A. Niemierko, L. Sequist, H. Shih, 2015, Neuro-oncology.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

A. Drilon, Keunchil Park, B. Cho, 2021, Clinical Cancer Research.

Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations

A. Giobbie-Hurder, S. Carter, A. Iafrate, 2021, Nature Cancer.

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC

A. Shaw, B. Yeap, S. Ou, 2020, JTO clinical and research reports.

Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors.

S. Digumarthy, A. Shaw, B. Yeap, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

C. Azzoli, L. Sequist, A. Shaw, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Developing biomarker-specific end points in lung cancer clinical trials

J. Neal, A. Shaw, J. Gainor, 2015, Nature Reviews Clinical Oncology.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Sean P. Brown, C. Azzoli, D. Cahill, 2018, Cancer discovery.

ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack

J. Gainor, M. Mooradian, 2017, The oncologist.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer

Julie M. Batten, S. Digumarthy, A. Iafrate, 2018, JCO precision oncology.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

C. Azzoli, L. Sequist, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).

Michael Thomas, R. Doebele, G. Curigliano, 2020 .

Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.

A. Shaw, B. Yeap, J. Lennerz, 2020 .

K. Reynolds, F. Fintelmann, T. Neilan, 2019, The oncologist.

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, L. Sequist, S. Ou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

A. Mansfield, R. Doebele, G. Curigliano, 2020, Journal of Clinical Oncology.

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

F. Hodi, Y. Bang, L. Chow, 2021, The Lancet. Oncology.

Postdiagnosis BMI Change Is Associated with Non–Small Cell Lung Cancer Survival

E. Loehrer, Yi Li, J. Gainor, 2021, Cancer Epidemiology, Biomarkers & Prevention.

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

H. Hirsch, F. Meric-Bernstam, G. Gibney, 2018 .

Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer.

E. Nadelmann, J. Gainor, L. Thompson, 2021, European journal of cancer.

Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.

J. Gainor, E. Friedman, Christine Saraceni, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

T. Choueiri, N. Agarwal, B. Halmos, 2021, Nature Reviews Clinical Oncology.

Acute nonrheumatic streptococcal myocarditis: STEMI mimic in young adults.

J. Ruskin, G. Upadhyay, J. Gainor, 2012, The American journal of medicine.

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer

A. Iafrate, A. Bardia, D. Juric, 2022, Therapeutic advances in medical oncology.

Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.

F. Fintelmann, J. Gainor, Gary X. Wang, 2017, AJR. American journal of roentgenology.

Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.

H. Shih, A. Shaw, B. Yeap, 2018, International journal of radiation oncology, biology, physics.

SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer

J. Gainor, F. Jin, K. Lee, 2021, Annals of Oncology.

Pharmacodynamic Biomarkers: Falling Short of the Mark?

D. Longo, B. Chabner, J. Gainor, 2014, Clinical Cancer Research.

Time to tackle the blood‐brain barrier in HER2‐mutant lung cancer

J. Gainor, Jessica J. Lin, 2019, Cancer.

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

A. Iafrate, A. Bardia, H. Willers, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy

H. Willers, V. Naranbhai, A. Balazs, 2021, Radiotherapy and Oncology.

Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC

S. Digumarthy, A. Shaw, B. Yeap, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors

J. Barrett, M. Hurwitz, H. Tawbi, 2023, Journal for ImmunoTherapy of Cancer.

Progresses Toward Precision Medicine in RET-altered Solid Tumors

A. Drilon, F. Penault-Llorca, F. André, 2020, Clinical Cancer Research.

Letter to the Editor Reply: Kleebayoon et al.

J. Gainor, 2023, Clinical Lung Cancer.

Sarcopenia, adiposity, and discrepancies in cystatin C versus creatinine-based eGFR in patients with cancer: a cross-sectional study

James E. Dinulos, D. Leaf, S. Gupta, 2023, medRxiv.

Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2

L. Munn, T. Stylianopoulos, V. Naranbhai, 2022, medRxiv.

Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT

S. Digumarthy, M. Mino‐Kenudson, M. Lanuti, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.

L. Sequist, J. Engelman, A. Shaw, 2016 .

Managing Resistance to EFGR- and ALK-Targeted Therapies.

P. Iyengar, C. Lovly, J. Gainor, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

L. Sequist, J. Engelman, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

T. Mok, Y. Wu, J. Gainor, 2022, Annals of Oncology.

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

M. Kris, V. Rusch, I. Wistuba, 2021 .

278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2020 .

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

G. Gibney, T. Seiwert, M. Callahan, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2018, Clinical Trials.

ALK Resistance Mutations in ALK-Positive Lung Cancer

Lauren L. Ritterhouse, S. Digumarthy, A. Iafrate, 2016 .

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion–positive solid tumors.

A. Mansfield, R. Doebele, G. Curigliano, 2020, Journal of Clinical Oncology.

Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

Linda T. Nieman, N. Hacohen, Keren Yizhak, 2023, bioRxiv.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.

Melissa L. Johnson, R. Gonzalez, A. Gollerkeri, 2017 .

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

J. Pons, P. Squifflet, W. Kim, 2020 .

Is there an app for that?

J. Gainor, Justin F Gainor, 2012, The oncologist.

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

J. Schellens, J. Soria, Sunil Sharma, 2016 .

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

S. Digumarthy, M. Hellmann, K. Kehl, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Activity of Alectinib in Advanced RET‐Rearranged Non–Small Cell Lung Cancer

S. Digumarthy, P. Brastianos, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice.

S. Digumarthy, M. Lanuti, D. Mendoza, 2022, AJR. American journal of roentgenology.

P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status

S. Digumarthy, M. Tolstorukov, A. Cherniack, 2021 .

Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.

R. Sullivan, K. Flaherty, C. Sadow, 2016 .

Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas

A. Iafrate, M. Mino‐Kenudson, M. L. Zhang, 2018, Modern Pathology.

ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

J. Gainor, Jessica J. Lin, 2018, The Lancet. Oncology.

Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.

M. Mino‐Kenudson, A. Shaw, M. Hellmann, 2018 .

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

T. R. Johnson, M. Mino‐Kenudson, B. Yeap, 2021, bioRxiv.

Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.

A. Shaw, B. Yeap, J. Lennerz, 2018 .

MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC

C. Rudin, P. Jänne, I. Wistuba, 2017 .

P1.04-21 The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

S. Digumarthy, M. Mino‐Kenudson, J. Gainor, 2018, Journal of Thoracic Oncology.

Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.

S. Digumarthy, M. Mino‐Kenudson, L. Sequist, 2014 .

Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)

N. Girard, Keunchil Park, T. Mok, 2019, Annals of Oncology.

Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression.

M. Mino‐Kenudson, E. Mark, J. Engelman, 2015 .

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Philip S. Yu, Sharon S. Choi, Omar H. Butt, 2023, BMC Cancer.

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

S. Digumarthy, C. Azzoli, M. Mino‐Kenudson, 2017, International journal of radiation oncology, biology, physics.

First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.

J. Gainor, Jessica J. Lin, 2022, The Lancet. Respiratory medicine.

Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression.

M. Mino‐Kenudson, E. Mark, J. Engelman, 2015 .

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

L. Sequist, J. Engelman, A. Shaw, 2015 .

Detection of Extrapulmonary Malignancy During Lung Cancer Screening: 5-Year Analysis at a Tertiary Hospital.

S. Digumarthy, J. Shepard, M. Gilman, 2020, Journal of the American College of Radiology : JACR.

J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer

A. Shaw, J. Gainor, 2017, The Lancet.

A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).

E. Vokes, N. Rizvi, P. Baas, 2015 .

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors

S. Ou, M. Brose, V. Subbiah, 2018, Clinical Trials.

Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

J. Burke, A. Tolcher, G. Gibney, 2017 .

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

B. Cho, N. Reguart, D. Morgensztern, 2021 .

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

S. Ramalingam, M. Hellmann, H. Borghaei, 2020 .

Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity.

P. Brastianos, C. Alvarez-Breckenridge, M. Strickland, 2022, Cancer discovery.

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

R. Deberardinis, Jing Wang, J. Minna, 2023, Cancer cell.

Keeping Expectations in Check With Immune Checkpoint Inhibitors.

R. Sullivan, J. Temel, J. Greer, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.

R. Sullivan, R. Govindan, Melissa L. Johnson, 2018 .

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, Y. Bang, 2019 .

Response to Provenzano et al. and De Carlo et al.

A. Drilon, J. Gainor, Jessica J. Lin, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.

S. Digumarthy, A. Drilon, J. Donington, 2022, Journal of Thoracic Oncology.

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Keunchil Park, T. Mok, Y. Ohe, 2016 .

Hospice use and end‐of‐life care among older patients with esophageal cancer

C. Kong, C. Hur, R. Nipp, 2018, Health science reports.

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

S. Digumarthy, L. Sequist, R. Heist, 2023, JTO clinical and research reports.

Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

A. Drilon, J. Wolf, B. Besse, 2020, Pneumologie.

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Christopher J. Ott, Chang S. Chan, M. Lawrence, 2023, Nature.

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

C. Azzoli, M. Mino‐Kenudson, L. Sequist, 2015 .

Abstract CT217: 3-year update of neoadjuvant atezolizumab + chemotherapy in patients with resectable non-small cell lung cancer

A. Saqi, N. Rizvi, J. Gainor, 2023, Cancer Research.

COVID-19 Infection in a Lung Cancer Patient Population: Incidence, Presentation and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.

S. Digumarthy, B. Little, F. Fintelmann, 2023, Clinical lung cancer.

Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor

Linda T. Nieman, A. Villani, G. Boland, 2023, bioRxiv.

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment

M. Mino‐Kenudson, E. Mark, J. Engelman, 2016, Journal of Thoracic Oncology.

Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies

A. Iafrate, V. Naranbhai, A. Balazs, 2023, Clinical Lung Cancer.

Letter to the Editor Reply: Kleebayoon et al.

J. Gainor, C. Meador, 2023, Clinical Lung Cancer.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J. Riess, M. Hellmann, H. Rizvi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

G. Getz, A. Iafrate, J. Engelman, 2016, The New England journal of medicine.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, J. Engelman, 2018, Cancer discovery.

984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)

J. Mazières, G. Lopes, M. Nowicka, 2022, Annals of Oncology.

Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.

L. Sequist, A. Shaw, R. Heist, 2018 .

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Jeffrey W. Clark, L. Sequist, J. Engelman, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution

S. Digumarthy, J. Gainor, Jessica J. Lin, 2023, NPJ precision oncology.

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

L. Sequist, A. Shaw, R. Heist, 2014 .

Hospice use and end‐of‐life care among older patients with esophageal cancer

C. Kong, C. Hur, R. Nipp, 2018, Health science reports.

498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

Y. Bang, J. Pons, P. Squifflet, 2021, Journal for ImmunoTherapy of Cancer.

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

K. Lewis, J. Goldman, S. Rothenberg, 2022, Clinical Cancer Research.

Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor

Linda T. Nieman, A. Villani, G. Boland, 2023, bioRxiv.